iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors

Bi-Huei Yang(Fate Therapeutics (United States)), Bahram Valamehr(Fate Therapeutics (United States))

Cell Reports Medicine

June 19, 2025

10.1016/j.xcrm.2025.102195

Cited by 3

Related Papers

Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy

|Cell stem cell|2021|153

A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors

|Med|2023|25

iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting

|Journal for ImmunoTherapy of Cancer|2023|21

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

|Blood|2020|8

iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma

|Frontiers in Immunology|2024|7